sabizabulin for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

VERU-111, 2022 NCT04842747

sabizabulin (n=134) vs. placebo (n=70)

randomized controlled trial

Studied treatment

daily oral doses of sabizabulin 9mg for 21 days

Control treatment

placebo

Patients

COVID-19 mild to moderate

Method

double-blind

27 centers, worldwide

met the prespecified superiority criterion for efficacy at the time of the interim analysis with 150 patients

Remark

planned interim analysis

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open